相关实验视频

Updated: Apr 10, 2026

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

基于MoSe₂SERS平台的简单血测试用于阿尔茨海默病的特定诊断

Yan Zhou¹, Jianyan Li², Tingting Zheng²

¹State Key Laboratory of Precision Spectroscopy, East China Normal University, Dongchuan Road 500, Shanghai 200241, P. R. China.

Chemical & biomedical imaging

|October 30, 2024

概括

研究人员开发了一种新型的鱼样化 (MoSe2) 微球平台,用于检测来自大脑的 (BD-tau),这是阿尔茨海默病的关键生物标志物. 这种基于SERS的平台显示了早期AD诊断的高灵敏度和选择性.

科学领域:

材料科学材料科学材料科学
生物技术是生物技术.
分析化学分析化学

背景情况:

大脑衍生性 (BD-tau) 是阿尔茨海默病 (AD) 诊断的关键生物标志物.
准确检测BD-tau对于区分神经系统疾病至关重要.
现有的检测方法需要提高灵敏度和选择性.

研究的目的:

为了合成类似海刺的化 (MoSe2) 微球,以增强SERS活性.
开发一个敏感和选择性的表面增强拉曼光谱 (SERS) 探测平台,用于BD-tau.
评估该平台在早期阿尔茨海默病诊断方面的潜力.

主要方法:

类似海的MoSe2微球的热水合成.
制造BD-tau SERS检测平台,使用阿巴胺-抗体三明治试验.
描述SERS活动和增强因子 (EF) 的特征.
检测线性,检测极限 (LOD) 和选择性的评估.

主要成果:

MoSe2微球表现出显著的SERS活动,EF为1.44 × 10^7.7.
开发的SERS平台显示BD-tau.的线性检测范围为0.05200.00 pM.
实现了0.028 pM的低检测极限 (LOD).
该平台显示出优异的选择性,并在小鼠血样本中启用了早期AD诊断.

结论:

类似海的MoSe2微球是有效的SERS基质.
基于MoSe2的SERS平台为BD-tau检测提供了高灵敏度和选择性.
这项技术在神经退行性疾病中对阿尔茨海默病的早期诊断和识别具有很大的潜力.

更多相关视频

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...